Cost-effectiveness of a predictive biomarker for bevacizumab responsiveness in the primary treatment of ovarian cancer

被引：1
|
作者：
Barnett, I. [1 ]
Alvarez-Secord, A. [2 ]
Cohn, D. [3 ]
Leath, C. [1 ]
Peterson, B. [2 ]
Myers, E. [2 ]
Havrilesky, L. [2 ]
机构：
[1] Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Ohio State Univ, Columbus, OH 43210 USA
来源：
GYNECOLOGIC ONCOLOGY | 2012年 / 125卷
关键词：
D O I：
10.1016/j.ygyno.2011.12.157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
156
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [11] Clinical outcomes and cost-effectiveness of primary treatment of ovarian cancer in North-Western Romania
    Onisim, Andrea
    Achimas-Cadariu, Patriciu
    Iancu, Mihaela
    Puscas, Emil
    Bodog, Alin
    Vlad, Catalin
    [J]. JOURNAL OF BUON, 2019, 24 (03): : 982 - 989
  • [12] Olaparib in combination with bevacizumab compared to bevacizumab monotherapy for the first-line maintenance treatment of advanced ovarian cancer: a cost-effectiveness analysis
    Fan, Lin
    Muston, Dominic
    Elsea, David
    El Moustaid, Fadoua
    Mihai, Adela
    Simmons, Daniel
    McLaurin, Kimmie
    Monberg, Matthew
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 162 : S216 - S217
  • [13] Cost-effectiveness analysis of VEGF-C: A novel predictive biomarker for response to bevacizumab in the neoadjuvant therapy of early breast cancer patients
    Blank, Patricia Renee
    Loibl, Sibylle
    Linderholm, Barbro Kristina
    Caramuta, Stefano
    Nekljudova, Valentina
    Szucs, Thomas D.
    van Stiphout, Joris
    Ademi, Zanfina
    Von Minckwitz, Gunter
    Schwenkglenks, Matthias
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [14] Cost-effectiveness of Ovarian Cancer Prevention Strategies
    Kwon, Janice S.
    [J]. CLINICAL OBSTETRICS AND GYNECOLOGY, 2017, 60 (04): : 780 - 788
  • [15] A Review of Cost-Effectiveness Studies in Ovarian Cancer
    Sfakianos, Gregory P.
    Havrilesky, Laura J.
    [J]. CANCER CONTROL, 2011, 18 (01) : 59 - 64
  • [16] Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan
    Shiroiwa, Takeru
    Fukuda, Takashi
    Tsutani, Kiichiro
    [J]. CLINICAL THERAPEUTICS, 2007, 29 (10) : 2256 - 2267
  • [17] COST-EFFECTIVENESS OF MULTIPLEXED PREDICTIVE BIOMARKER SCREENING IN NON-SMALL CELL LUNG CANCER
    Romanus, D.
    Cardarella, S.
    Cutler, D.
    Landrum, M. B.
    Lindeman, N.
    Gazelle, G. S.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A204 - A204
  • [18] IMPACT OF BEVACIZUMAB IN THE PRIMARY TREATMENT OF OVARIAN CANCER
    Matsumoto, T.
    Usami, T.
    Yasuoka, T.
    Inoue, A.
    Matsubara, Y.
    Fujioka, T.
    Matsubara, K. I.
    Sugiyama, T.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 763 - 763
  • [19] Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences
    Ruiz-Sanchez, Daniel
    Iglesias Peinado, Irene
    Alaguero-Calero, Miguel
    Jose Sastre-Heres, Alejandro
    Garcia Diez, Benito
    Pena-Diaz, Jaime
    [J]. ONCOLOGY LETTERS, 2016, 12 (03) : 1935 - 1940
  • [20] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
    Burger, Robert A.
    Brady, Mark F.
    Bookman, Michael A.
    Fleming, Gini F.
    Monk, Bradley J.
    Huang, Helen
    Mannel, Robert S.
    Homesley, Howard D.
    Fowler, Jeffrey
    Greer, Benjamin E.
    Boente, Matthew
    Birrer, Michael J.
    Liang, Sharon X.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26): : 2473 - 2483
12345